StockData
bioAffinity Technologies, Inc. logo

bioAffinity Technologies, Inc. (BIAF) stock

BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 4/3068% below fair value
$1.85−0.30 (-13.95%)

Close on Nov 19, 2026Market cap $14.99MP/E –Yield –

bioAffinity Technologies operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

bioAffinity Technologies's operating income for the twelve months ending Jun 30, 2026 was -$12.38M. For fiscal 2025 it was -$10.57M. The highest annual figure on record is -$2.21M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.57M–
FY2024Dec 31, 2024-$8.95M–
FY2023Dec 31, 2023-$7.97M–
FY2022Dec 31, 2022-$4.01M–
FY2021Dec 31, 2021-$2.21M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.33M–
Q1 FY2026Mar 31, 2026-$3.62M–
Q4 FY2025Dec 31, 2025-$3.14M–
Q3 FY2025Sep 30, 2025-$2.29M–
Q2 FY2025Jun 30, 2025-$2.52M–
Q1 FY2025Mar 31, 2025-$2.63M–
Q4 FY2024Dec 31, 2024-$2.95M–
Q3 FY2024Sep 30, 2024-$1.97M–
Q2 FY2024Jun 30, 2024-$2.09M–
Q1 FY2024Mar 31, 2024-$1.95M–
Q4 FY2023Dec 31, 2023-$2.34M–
Q3 FY2023Sep 30, 2023-$2.29M–
Q2 FY2023Jun 30, 2023-$1.78M–
Q1 FY2023Mar 31, 2023-$1.56M–
Q4 FY2022Dec 31, 2022-$1.62M–
Q3 FY2022Sep 30, 2022-$976.16K–
Q2 FY2022Jun 30, 2022-$684.12K–
Q1 FY2022Mar 31, 2022-$727.04K–
Q4 FY2021Dec 31, 2021-$659.75K–
Q3 FY2021Sep 30, 2021-$526.29K–

More bioAffinity Technologies figures

See a number that looks wrong?